Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 ? February 1 in Paris, ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...

New pooled data from three Galderma studies of the Restylane portfolio will be presented, demonstrating that treatments with Restylane RefyneTM and Restylane DefyneTM not only enhance ...

(BUSINESS WIRE )--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® LyftTM or ContourTM in combination with Sculptra® in patients ...

including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Mast ZUG, Switzerland, January 14, 2025--Galderma ...

"We initiated this trial because we have the unique expertise, capability, and products needed to rapidly respond to the evolving needs of patients and healthcare professionals. It is encouraging to ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Mast ZUG, Switzerland, December 13, 2024--Galderma ...

Galderma Group AG operates as a dermatology ... Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Three-month interim data showed hyaluronic acid ...